An investigator reported updated findings from the phase 2/3 study QUILT 3.032 using a July 15, 2024 data cutoff.

Recurrence in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer is common, and there have been a lack of alternative treatments to TURBT.

BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.

Data on the efficacy of radical prostatectomy in managing clinically node-positive prostate cancer have been limited.

The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.

Given a global shortage of bacillus Calmette-Guérin (BCG) treatment, it has been important to determine whether there are effective alternatives for intermediate-risk non-muscle-invasive bladder ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Fibrate therapy may lower the risks of mortality and progression to end-stage kidney disease (ESKD), despite raising the risk for new onset stage 3 or higher chronic kidney disease (CKD), a new study ...

(HealthDay News) — The prevalence of depression among adolescents and adults aged 12 years and older during August 2021 to August 2023 was 13.1 percent, a 60 percent increase from 2013-2014, according ...

There may be “substantial delays” between when a drug is granted accelerated approval for a cancer indication, when negative trial results are released, and when the accelerated approval of the drug ...

Prevalence of smoking continued to drop during pandemic, but prevalence of excess body weight, HPV vaccination remained stable.

Residual nodal disease following neoadjuvant chemotherapy for upper tract urothelial carcinoma (UTUC) indicates an especially high-risk population.